Corient Private Wealth
XGN icon

Corient Private Wealth’s Exagen XGN Stock Holding History

Corient Private Wealth’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.6K Hold
11,093
– – ﹤0.01% 2987
2026
Q1 		$33.3K Sell
11,093
-3,462
-24% -$13.4K ﹤0.01% 2770
2025
Q4 		$88.5K Buy
+14,555
New +$132K ﹤0.01% 2564
2025
Q3 		– Sell
-14,555
Closed -$102K – 2697
2025
Q2 		$102K Hold
14,555
– – ﹤0.01% 2325
2025
Q1 		$52.3K Buy
14,555
+3,462
+31% +$13.1K ﹤0.01% 2222
2024
Q4 		$45.5K Buy
+11,093
New +$40K ﹤0.01% 2284

Other funds holding XGN

WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Corient Private Wealth's XGN Position: Q2 2026 in Review

Corient Private Wealth held its Exagen (XGN) position steady in Q2 2026 at 11,093 shares worth $51.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2987.

Corient Private Wealth first reported a position in XGN in Q4 2024 and has held it in 6 quarters since. The position peaked at $102K in Q2 2025. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

  • Corient Private Wealth held 11,093 shares of Exagen worth $51.6K as of Q2 2026.
  • Corient Private Wealth left its Exagen share count unchanged in Q2 2026.
  • Exagen made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2987 holding.
  • Corient Private Wealth first reported a position in Exagen in Q4 2024 and has held it in 6 quarters since.
  • Corient Private Wealth's Exagen position peaked at $102K in Q2 2025.
  • 57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.